; Grant and Treasurer, 1993) , the use of cleaner wrasse (Costello, 1993; Treasurer, 1993; Kvenseth, 1997b) , good husbandry practices (Kvenseth, 1997a; Treasurer, 1998) and chemotherapy (Roth et ah, 1993) . While direct loss of stock from mortality and indirect losses from reduced growth represent the largest cost associated with sea lice infestations, they are both intricately linked to the cost and availability of chemotherapeutants used to manwere first reported from salmon culture during the early 1970s in Norway following the development of systems for the intensive rearing of salmon in marine net-pens (Hastein and Bergsjo, 1976) . Since then sea lice infestations have been reported from most, if not all, regions where salmon are farmed (Roth et ah, 1993) .
In economic terms, sea lice outbreaks can be devastating. In 1996, annual costs associated with direct losses, treatment, and lost growth have been estimated at US $33.4 million (=£20 million) in Norway (Kvenseth, 1997a) , US $25 million (=£15 million) in Scotland (Dear, 1997) , and US $16 million (=£10 million) in Canada (Roth, unpublished data I r e l a n d ; t h e r a p e u t a n t I c e l a n d : no r e q u i r e m e n t Z e a l a n d : C h e m o t h e r a p e u t a n t s in C l i n i c a l Usage 1 9 9 7 / 9 8 C o u n t r y O r g a n o p h o s p h a t e s P y r e t h r i n s I r e l a n d C h e m o t h e r a p e u t a n t s C h e m o t h e r a p e u t a n t (Brackett and Roth, 1999 (Grave et ah, 1991; Kvenseth, 1997a) . Neither of these latter compounds, however, are effective against larval lice (Johnson et ah, 1993a; Hogans, 1994 (Jones et ah, 1992 
